Cargando…

Treatment-Emergent Mutations and Resistance in HIV-Infected Children Treated with Fosamprenavir-Containing Antiretroviral Regimens

Treatment-emergent mutations and drug resistance were analyzed in virus from HIV-infected children meeting virologic failure (VF) criteria over 48 weeks following treatment with unboosted fosamprenavir or fosamprenavir/ritonavir-containing regimens in studies APV20002 and APV29005. Both antiretrovir...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ross, Lisa L, Cotton, Mark F, Cassim, Haseena, Voronin, Eugeny, Givens, Naomi, Sievers, Jorg, Cheng, Katharine Y
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Bentham Open 2015
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4484231/ https://www.ncbi.nlm.nih.gov/pubmed/26157536 http://dx.doi.org/10.2174/1874613601509010038

Ejemplares similares

Pharmacokinetics, Safety and Antiviral Activity of Fosamprenavir/Ritonavir-containing Regimens in HIV-infected Children Aged 4 Weeks to 2 Years—48-week Study Data
por: Cotton, Mark, et al.
Publicado: (2014)

Pharmacokinetics and 48-week Safety and Antiviral Activity of Fosamprenavir-containing Regimens in HIV-infected 2- to 18-year-old Children
por: Fortuny, Claudia, et al.
Publicado: (2014)

Prevalence of resistance and HIV-1 protease mutation patterns after failures with fosamprenavir-containing regimens
por: Marcelin, AG, et al.
Publicado: (2010)

SUPPORT: 48-week results of fosamprenavir/ritonavir vs efavirenz with abacavir/lamivudine in under-represented, antiretroviral-naïve patients
por: Kumar, P, et al.
Publicado: (2010)

Post-licensing safety of fosamprenavir in HIV-infected children in Europe†
por: Judd, Ali, et al.
Publicado: (2014)

A retrospective case-cohort study comparing treatment outcomes in abacavir versus stavudine containing first line antiretroviral treatment regimens in children <3yrs old, at a paediatric programme based in Soweto, South Africa
por: Cassim, Haseena, et al.
Publicado: (2017)

Evaluation of cardiovascular biomarkers in a randomized trial of fosamprenavir/ritonavir vs. efavirenz with abacavir/lamivudine in underrepresented, antiretroviral-naïve, HIV-infected patients (SUPPORT): 96-week results
por: Kumar, Princy, et al.
Publicado: (2013)

Once-daily fosamprenavir with ritonavir in the treatment of HIV infection in therapy-naïve patients
por: Flamholc, Leo, et al.
Publicado: (2008)

Efficacy and safety of a dual boosted protease inhibitor-based regimen, atazanavir and fosamprenavir/ritonavir, against HIV: experience in a pediatric population
por: Rusconi, Stefano, et al.
Publicado: (2012)

Changes in lipid profiles after switching to a protease inhibitor-containing cART - unfavourable effect of fosamprenavir in obese patients
por: Gyalrong-Steur, M, et al.
Publicado: (2011)

Fosamprenavir or atazanavir once daily boosted with ritonavir 100 mg, plus tenofovir/emtricitabine, for the initial treatment of HIV infection: 48-week results of ALERT
por: Smith, Kimberly Y, et al.
Publicado: (2008)

Renal safety of tenofovir containing antiretroviral regimen in a Singapore cohort
por: Chua, Arlene C, et al.
Publicado: (2012)

Effectiveness of four antiretroviral regimens for treating people living with HIV
por: Cavalcanti, Aracele Tenório de Almeida e, et al.
Publicado: (2020)

Risk of Cardiovascular Events Among Patients Initiating Efavirenz-Containing Versus Efavirenz-Free Antiretroviral Regimens
por: Rosenblatt, Lisa, et al.
Publicado: (2016)

Patterns of emergent resistance-associated mutations after initiation of non-nucleoside reverse-transcriptase inhibitor-containing antiretroviral regimens in Taiwan: a multicenter cohort study
por: Cheng, Chien-Yu, et al.
Publicado: (2018)

Fecal Bacterial Communities in treated HIV infected individuals on two antiretroviral regimens
por: Pinto-Cardoso, Sandra, et al.
Publicado: (2017)

Persistence of Human Immunodeficiency Virus-1 Drug Resistance Mutations in Proviral Deoxyribonucleic Acid After Virologic Failure of Efavirenz-Containing Antiretroviral Regimens
por: De La Cruz, Justin, et al.
Publicado: (2019)

Antiretroviral Treatment Simplification With 2-Drug Regimens: Impact of Transmitted Drug Resistance Mutations
por: Kessler, Harald H, et al.
Publicado: (2019)

Renal Safety of a Tenofovir-Containing First Line Regimen: Experience from an Antiretroviral Cohort in Rural Lesotho
por: Bygrave, Helen, et al.
Publicado: (2011)

Risk of Liver Fibrosis in Hepatitis B Virus and HIV Coinfected Youths Receiving Tenofovir-Containing Antiretroviral Regimen
por: Aurpibul, Linda, et al.
Publicado: (2019)

107. Impact of Switching to an Antiretroviral Regimen Containing Tenofovir Alafenamide on Weight Gain and Development of Metabolic Side Effects
por: Darnell, Julia, et al.
Publicado: (2020)

Antiretroviral regimen complexity as a predictor of adherence
por: Boyle, C, et al.
Publicado: (2010)

Comparison of Antiretroviral Regimens: Adverse Effects and Tolerability Failure that Cause Regimen Switching
por: Kim, Min Jung, et al.
Publicado: (2015)

Frequency of Antiretroviral Resistance Mutations among Infants Exposed to Single-Dose Nevirapine and Short Course Maternal Antiretroviral Regimens: ACTG A5207
por: Hitti, Jane, et al.
Publicado: (2014)

Incidence of hypertension in people with HIV who are treated with integrase inhibitors versus other antiretroviral regimens in the RESPOND cohort consortium
por: Byonanebye, Dathan M., et al.
Publicado: (2022)

Safety and efficacy after switch to a saquinavir-containing antiretroviral regimen in protease inhibitor pretreated HIV-positive patients
por: Stephan, C, et al.
Publicado: (2010)

Efficacy of Dolutegravir versus Darunavir in Antiretroviral First-Line Regimens According to Resistance Mutations and Viral Subtype
por: Salvo, Pierluigi Francesco, et al.
Publicado: (2023)

Effectiveness of antiretroviral therapy in the single-tablet regimen era
por: Costa, Juliana de Oliveira, et al.
Publicado: (2018)

Towards an ideal antiretroviral regimen for the global HIV epidemic
por: Grinsztejn, Beatriz, et al.
Publicado: (2017)

Changes from 2000 to 2009 in the Prevalence of HIV-1 Containing Drug Resistance-Associated Mutations from Antiretroviral Therapy-Naive, HIV-1-Infected Patients in the United States
por: Ross, Lisa L., et al.
Publicado: (2018)

Rituximab-Containing Treatment Regimens May Imply a Long-Term Risk for Difficult-To-Treat Chronic Hepatitis E
por: Schulz, Marten, et al.
Publicado: (2020)

Comparison of Tolerability and Impact on Metabolic Profiles of Antiretroviral Regimens Containing Darunavir/Ritonavir or Darunavir/Cobicistat in Romanian HIV Infected Patients
por: Marin, Ruxandra-Cristina, et al.
Publicado: (2021)

Switch from a ritonavir to a cobicistat containing antiretroviral regimen and impact on tacrolimus levels in a kidney transplant recipient
por: Erba, Andrea, et al.
Publicado: (2023)

Designing a Predictive Model for Antiretroviral Regimen at the Antiretroviral Therapy Center in Chiro Hospital, Ethiopia
por: Nemomsa, Gadissa, et al.
Publicado: (2021)

Risk of cardiovascular events among patients with HIV treated with atazanavir-containing regimens: a retrospective cohort study
por: Rosenblatt, Lisa, et al.
Publicado: (2016)

The Safety of Substitution of Antiretroviral Regimen in Non-Clinical Trial Settings in Asian Countries
por: Jung, In Young, et al.
Publicado: (2017)

From antiretroviral therapy access to provision of third line regimens: evidence of HIV Drug resistance mutations to first and second line regimens among Ugandan adults
por: Namakoola, Ivan, et al.
Publicado: (2016)

The rainbow cohort: 96 week follow-up of saquinavir-containing regimens in previously antiretroviral therapy (ART)-naïve and pre-treated but protease inhibitor (PI)- naïve hiv-infected patients
por: Knechten, H, et al.
Publicado: (2011)

Duration of antiretroviral regimens in treatment-experienced patients in clinical practice
por: Vilaplana, Vicente Escudero, et al.
Publicado: (2010)

Medication Possession Ratio Predicts Antiretroviral Regimens Persistence in Peru
por: Salinas, Jorge L., et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_ta0fvjop6dei3bcbkqi43ibu9s